Information de reference pour ce titreAccession Number: | 00004548-201107000-00024.
|
Author: | Patel, Nimish 1; Harrington, Susan 2; Dihmess, Amanda 1; Woo, Benjamin 1; Masoud, Rasha 1; Martis, Pearl 1; Fiorenza, Mallory 1; Graffunder, Eileen 3; Evans, Ann 3; McNutt, Louise-Anne 4; Lodise, Thomas P. 1,*
|
Institution: | (1) Pharmacy Practice Department, Albany College of Pharmacy and Health Sciences, Albany, NY, USA (2) Department of Pathology and Laboratory Medicine, Albany Medical Center Hospital, Albany, NY, USA (3) Department of Epidemiology, Albany Medical Center Hospital, Albany, NY, USA (4) Department of Epidemiology, School of Public Health, University at Albany, State University of New York, Rensselaer, NY, USA
|
Title: | |
Source: | Journal of Antimicrobial Chemotherapy. 66(7):1600-1608, July 2011.
|
Abstract: | Objectives: Despite the increasing incidence of carbapenem-intermediate or -resistant Enterobacteriaceae (CIRE), risk factors associated with CIRE infections have not been well defined. This study characterizes factors associated with CIRE among two different source populations.
Methods: A case-control study was performed at a tertiary care medical centre between January 2005 and December 2009. Cases were adults with a culture-confirmed Enterobacteriaceae infection with reduced susceptibility to meropenem or ertapenem. The CIRE cases were matched 1:1 to patients from two different control series: (i) those with carbapenem-susceptible Enterobacteriaceae (CSE) infections; and (ii) inpatients residing on the same ward within 30 days of CIRE culture date. Logistic regression was used to identify variables independently associated with CIRE among each source population. Restricted multivariate analyses were performed to determine if covariates predictive of CIRE varied by infecting organism or presence of the blaKPC gene.
Results: There were 102 cases of CIRE during the study period. The only covariate independently associated with CIRE in all multivariate analyses was the cumulative number of prior antibiotic exposures. Compared with CSE controls, the odds ratios (95% confidence interval) were 1.43 (1.19-1.72), 2.05 (1.70-2.47) and 2.93 (2.43-3.53) for 1, 2 and >=3 antibiotic exposures, respectively. The strength of this association was comparable for the hospitalized control group and analyses stratified by organism and presence of the blaKPC gene.
Conclusions: A patient's cumulative antibiotic exposure history is likely to be more important than any one specific exposure when determining the likelihood of developing a CIRE infection.
(C) British Society for Antimicrobial Chemotherapy 2011. Published by Oxford University Press. All rights reserved.
|
Author Keywords: | Klebsiella pneumoniae; K. pneumoniae; cumulative antibiotic exposures.
|
References: | 1. . National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004 Am J Infect Control. 2004;32:470-85 doi:10.1016/j.ajic.2004.10.001
2. Karlowsky JA, Jones ME, Thornsberry C, et al. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 Antimicrob Agents Chemother. 2003;47:1672-80 doi:10.1128/AAC.47.5.1672-1680.2003
3. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents J Antimicrob Chemother. 2005;56:128-32 doi:10.1093/jac/dki175
4. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection Antimicrob Agents Chemother. 2005;49:3018-20 doi:10.1128/AAC.49.7.3018-3020.2005
5. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium Arch Intern Med. 2005;165:1430-5 doi:10.1001/archinte.165.12.1430
6. Bratu S, Landman D, Alam M, et al. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York Antimicrob Agents Chemother. 2005;49:776-8 doi:10.1128/AAC.49.2.776-778.2005
7. Cuzon G, Naas T, Truong H, et al. Worldwide diversity of Klebsiella pneumoniae that produce [beta]-lactamase blaKPC-2 gene Emerg Infect Dis. 2010;16:1349-56
8. Goren MG, Navon-Venezia S, Chmelnitsky I, et al. Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv medical center, 2005 to 2008 Antimicrob Agents Chemother. 2010;54:2687-91 doi:10.1128/AAC.01359-09
9. Wendt C, Schutt S, Dalpke AH, et al. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany Eur J Clin Microbiol Infect Dis. 2010;29:563-70 doi:10.1007/s10096-010-0896-0
10. Gasink LB, Edelstein PH, Lautenbach E, et al. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae Infect Control Hosp Epidemiol. 2009;30:1180-5 doi:10.1086/648451
11. Hussein K, Sprecher H, Mashiach T, et al. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns Infect Control Hosp Epidemiol. 2009;30:666-71 doi:10.1086/598244
12. Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-[beta]-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes Infect Control Hosp Epidemiol. 2010;31:1250-6 doi:10.1086/657135
13. Zarkotou O, Pournaras S, Voulgari E, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study J Clin Microbiol. 2010;48:2271-4 doi:10.1128/JCM.02301-09
14. Harris AD, Carmeli Y, Samore MH, et al. Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms Infect Control Hosp Epidemiol. 2005;26:342-5 doi:10.1086/502549
15. Harris AD, Samore MH, Lipsitch M, et al. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli Clin Infect Dis. 2002;34:1558-63 doi:10.1086/340533
16. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients Chest. 1999;115:462-74 doi:10.1378/chest.115.2.462
17. Garner JS, Jarvis WR, Emori TG, et al.Olmsted RN CDC definitions of nosocomial infections APIC Infection Control and Applied Epidemiology: Principles and Practice. 1996 St Louis, MO Mosby:A-1-20
18. Wexler HM. In vitro activity of ertapenem: review of recent studies J Antimicrob Chemother. 2004;53(Suppl 2):ii11-21 doi:10.1093/jac/dkh204
19. Hyle EP, Gasink LB, Linkin DR, et al. Use of different thresholds of prior antimicrobial use in defining exposure: impact on the association between antimicrobial use and antimicrobial resistance J Infect. 2007;55:414-8 doi:10.1016/j.jinf.2007.07.005
20. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system Crit Care Med. 1985;13:818-29 doi:10.1097/00003246-198510000-00009
21. Thom KA, Shardell MD, Osih RB, et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points Infect Control Hosp Epidemiol. 2008;29:1048-53 doi:10.1086/591453
22. McGregor JC, Perencevich EN, Furuno JP, et al. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections J Clin Epidemiol. 2006;59:1266-73 doi:10.1016/j.jclinepi.2006.01.016
23. Nattanmai GV, Kohlerschmidt DJ, Wroblewski D, et al. Carbapenem-resistant Klebsiella pneumoniae (KPC-KP) in Upstate New York, 2005-2007Posters of the One hundred and eighth Meeting of the American Society for Microbiology, Boston, MA, 2008 Washington, DC, USA Poster C-279. American Society for Microbiology
24. Zhang H, Burthon S Recursive Partitioning in the Health Sciences. 1999 New York, NY Springer
25. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study J Antimicrob Chemother. 2007;60:1124-30 doi:10.1093/jac/dkm356
26. Hyle EP, Ferraro MJ, Silver M, et al. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes Infect Control Hosp Epidemiol. 2010;31:1242-9 doi:10.1086/657138
27. Jeon MH, Choi SH, Kwak YG, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients Diagn Microbiol Infect Dis. 2008;62:402-6 doi:10.1016/j.diagmicrobio.2008.08.014
28. Lodise TP Jr, Miller C, Patel N, et al. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates Infect Control Hosp Epidemiol. 2007;28:959-65 doi:10.1086/518972
29. Lodise TP, Miller CD, Graves J, et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance Antimicrob Agents Chemother. 2007;51:417-22 doi:10.1128/AAC.00851-06
30. Patel N, McNutt LA, Lodise TP. Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa Antimicrob Agents Chemother. 2008;52:2933-6 doi:10.1128/AAC.00456-08
|
Language: | English.
|
Document Type: | Original research.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences. Pharmacology.
|
ISSN: | 0305-7453
|
NLM Journal Code: | hd7, 7513617
|
DOI Number: | https://dx.doi.org/10.1093/jac/d...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|